Intranasal octreotide - Dauntless Pharmaceuticals

Drug Profile

Intranasal octreotide - Dauntless Pharmaceuticals

Alternative Names: Dauntless 1; Dauntless 2; DP 1038

Latest Information Update: 13 Feb 2017

Price : $50

At a glance

  • Originator Dauntless Pharmaceuticals
  • Class Antineoplastics; Antisecretories; Cyclic peptides; Indoles; Somatostatins
  • Mechanism of Action Growth hormone releasing factor antagonists; Somatostatin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 01 Jan 2017 Phase-I clinical trials in Cancer (In adults) in USA (Intranasal) (NCT03031535)
  • 06 Aug 2015 Dauntless Pharmaceuticals in-licenses Intravail® technology from Aegis Therapeutics
  • 06 Aug 2015 Dauntless Pharmaceuticals plans a phase I trial for Cancer(Dauntless Pharmaceuticals website, August 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top